Predictive Oncology (POAI) 10-K 15 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 15, 2017	Jun. 30, 2016
Document Information [Line Items]
Entity Registrant Name	Skyline Medical Inc.
Entity Central Index Key	1,446,159
Trading Symbol	skln
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		6,489,428
Entity Public Float			$ 11,767,746
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
ASSETS
Cash & cash equivalents	$ 1,764,090	$ 4,856,232
Certificates of deposit	100,000
Marketable securities	284,329
Accounts Receivable	38,919	38,283
Inventories	272,208	231,740
Prepaid Expense and other assets	148,637	271,579
Total Current Assets	2,608,183	5,397,834
Fixed Assets, net	101,496	139,598
Intangibles, net	97,867	94,987
Total Assets	2,807,546	5,632,419
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	220,112	650,413
Accrued Expenses	1,346,105	864,295
Deferred Revenue	7,998	5,000
Total Current Liabilities	1,574,215	1,519,708
Accrued Expenses	309,649
Total Liabilities	1,883,864	1,519,708
Commitments and Contingencies
Common Stock, $.01 par value, 24,000,000 authorized, 4,564,428 and 208,258 outstanding	45,644	2,080
Additional paid-in capital	(47,894,196)	(44,584,118)
Accumulated deficit	47,018,451	40,492,437
Accumulated Other Comprehensive Income	1,501
Total Stockholders' Equity	923,682	4,112,711
Total Liabilities and Stockholders' Equity	2,807,546	5,632,419
Series B Convertible Preferred Stock [Member]
LIABILITIES AND STOCKHOLDERS' EQUITY
Series B Convertible Preferred Stock, $.01 par value, 20,000,000 authorized, 79,246 and 1,895,010 outstanding	$ 792	$ 18,950

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	24,000,000	24,000,000
Common stock, shares outstanding (in shares)	4,564,428	208,258
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	1,895,010

Statements of Comprehensive Inc

Statements of Comprehensive Income (Loss) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue	$ 456,495	$ 654,354
Cost of goods sold	181,620	303,982
Gross margin	274,875	350,372
General and administrative expense	5,174,799	3,399,339
Operations expense	1,158,117	846,687
Sales and marketing expense	467,970	503,989
Interest expense	3	390,887
Total Expense	6,800,889	5,140,902
Net loss available to common shareholders	(6,526,014)	(4,790,530)
Unrealized gain (loss) from marketable securities	1,501
Comprehensive loss	$ (6,524,513)	$ (4,790,530)
Loss per common share - basic and diluted (in dollars per share)	$ (2.31)	$ (30.86)
Weighted average shares used in computation - basic and diluted (in shares)	2,823,345	155,233

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($)	Series A Convertible Preferred Stock [Member]Stock Conversion 1 [Member]Common Stock [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 1 [Member]Additional Paid-in Capital [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 2 [Member]Common Stock [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 2 [Member]Additional Paid-in Capital [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 2 [Member]Retained Earnings [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 2 [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 3 [Member]Common Stock [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 3 [Member]Additional Paid-in Capital [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 3 [Member]Retained Earnings [Member]	Series A Convertible Preferred Stock [Member]Stock Conversion 3 [Member]	Note Conversion 1 [Member]Common Stock [Member]	Note Conversion 1 [Member]Additional Paid-in Capital [Member]	Note Conversion 1 [Member]	Note Conversion 2 [Member]Common Stock [Member]	Note Conversion 2 [Member]Additional Paid-in Capital [Member]	Note Conversion 2 [Member]	Note Conversion 3 [Member]Common Stock [Member]	Note Conversion 3 [Member]Additional Paid-in Capital [Member]	Note Conversion 3 [Member]	Note Conversion 4 [Member]Common Stock [Member]	Note Conversion 4 [Member]Additional Paid-in Capital [Member]	Note Conversion 4 [Member]	Note Conversion 5 [Member]Common Stock [Member]	Note Conversion 5 [Member]Additional Paid-in Capital [Member]	Note Conversion 5 [Member]	Note Conversion 6 [Member]Common Stock [Member]	Note Conversion 6 [Member]Additional Paid-in Capital [Member]	Note Conversion 6 [Member]	Note Conversion 7 [Member]Common Stock [Member]	Note Conversion 7 [Member]Additional Paid-in Capital [Member]	Note Conversion 7 [Member]	Note Conversion 8 [Member]Common Stock [Member]	Note Conversion 8 [Member]Additional Paid-in Capital [Member]	Note Conversion 8 [Member]	Note Conversion 9 [Member]Common Stock [Member]	Note Conversion 9 [Member]Additional Paid-in Capital [Member]	Note Conversion 9 [Member]	Note Conversion 10 [Member]Common Stock [Member]	Note Conversion 10 [Member]Additional Paid-in Capital [Member]	Note Conversion 10 [Member]	Series B Warrants [Member]Common Stock [Member]	Series B Warrants [Member]Additional Paid-in Capital [Member]	Series B Warrants [Member]	Investment Banker [Member]Common Stock [Member]	Investment Banker [Member]Additional Paid-in Capital [Member]	Investment Banker [Member]	Investor Relations Consultant [Member]Common Stock [Member]	Investor Relations Consultant [Member]Additional Paid-in Capital [Member]	Investor Relations Consultant [Member]	GLG Pharma, LLC. [Member]Common Stock [Member]	GLG Pharma, LLC. [Member]	Former CEO [Member]Common Stock [Member]	Former CEO [Member]Additional Paid-in Capital [Member]	Former CEO [Member]	The 2016 Registered Direct Offering [Member]Common Stock [Member]	The 2016 Registered Direct Offering [Member]Additional Paid-in Capital [Member]	The 2016 Registered Direct Offering [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2014																																																										$ 206	$ 1,237	$ 30,123,436	$ (35,641,105)		$ (5,516,227)
Balance (in shares) at Dec. 31, 2014																																																											123,711
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares (in shares)	125		125				125
Shares issued to 16 shareholders of Series A Convertible Preferred Stock Adjustment as converted to common shares	$ 1	$ (1)	$ 1	$ 30,399	$ (30,401)	$ (1)	$ 1	$ 30,401	$ (30,401)	$ 1
Reduction in escrow account per settlement agreement (in shares)																																																											(356)
Reduction in escrow account per settlement agreement																																																											$ (4)	(6,663)			(6,667)
Shares issued for a note conversion (in shares)											138			270			413			484			622			1,400			3,520			595			520			646
Shares issued for a note conversion											$ 1	$ 9,999	$ 10,000	$ 3	$ 19,997	$ 20,000	$ 4	$ 29,996	$ 30,000	$ 5	$ 33,473	$ 33,478	$ 6	$ 34,994	$ 35,000	$ 14	$ 69,986	$ 70,000	$ 35	$ 199,965	$ 200,000	$ 6	$ 29,994	$ 30,000	$ 5	$ 24,995	$ 25,000	$ 6	$ 29,994	$ 30,000
Vesting Expense																																																												871,877			871,877
Shares issued in public offering, net.																																																										16,667	$ 667	13,043,546			13,060,880
Shares issued in public offering, net. (in shares)																																																											66,667
Preferred stock conversion																																																										2,077	$ 91	(2,168)
Preferred stock conversion (in shares)																																																											9,134
Series A warrant exercise (in shares)																																																											120
Series A warrant exercise																																																											$ 1	9,899			9,900
Net loss																																																													(4,790,530)		(4,790,530)
Balance at Dec. 31, 2015																																																										18,950	$ 2,080	44,584,118	(40,492,437)		4,112,711
Balance (in shares) at Dec. 31, 2015																																																											208,259
Stock Issued During Period Shares Warrants Exercised																																																											120
Shares issued for cashless Series B warrant exercises per the tender offer exchange																																																											$ 1	9,899			9,900
Unrealized gain from marketable securities
Vesting Expense																																																												165,271			165,271
Shares issued in public offering, net.																																															$ 260	$ 116,740	$ 117,000	$ 4,000	$ 4,000	$ 200	$ 90,151	$ 90,351	$ 7,570	$ 1,618,335	$ 1,625,905
Shares issued in public offering, net. (in shares)																																															26,000			400,000		20,000			756,999
Preferred stock conversion																																																										(18,158)	$ 664	17,494
Preferred stock conversion (in shares)																																																											66,396
Series A warrant exercise (in shares)																																									628,237																		2,318,663
Series A warrant exercise																																									$ 6,282	$ 150,777	$ 157,059																$ 23,187	556,479			579,666
Net loss																																																													(6,526,014)		(6,526,014)
Balance at Dec. 31, 2016																																																										$ 792	$ 45,644	47,894,196	$ (47,018,451)	$ 1,501	923,682
Balance (in shares) at Dec. 31, 2016																																																											4,564,428
Shares issued for two options exercised at $65.75 per share (in shares)																																																											1,312
Shares issued for two options exercised at $65.75 per share																																																											$ 13	86,240			86,253
Stock Issued During Period Shares Warrants Exercised																																									628,237																		2,318,663
Shares issued for cashless Series B warrant exercises per the tender offer exchange																																									$ 6,282	$ 150,777	$ 157,059																$ 23,187	556,479			579,666
Shares Issued (in shares)																																												135,995
Shares Issued																																												$ 1,360	$ 508,620	$ 509,980
Unrealized gain from marketable securities																																																														$ 1,501	1,501
Corrections due to rounding for reverse split and DTCC increase (in shares)																																																											2,567
Corrections due to rounding for reverse split and DTCC increase																																																											$ 28	$ (29)			$ (1)

Statements of Stockholders' Eq6

Statements of Stockholders' Equity (Deficit) (Parentheticals)	12 Months Ended
	Dec. 31, 2015$ / shares
Series A Convertible Preferred Stock [Member] | Stock Conversion 1 [Member]
Number of shareholders	16
Series A convertible preferred stock dividends (in dollars per share)	$ 243.75
Series A Convertible Preferred Stock [Member] | Stock Conversion 2 [Member]
Number of shareholders	16
Series A convertible preferred stock dividends (in dollars per share)	$ 243.75
Series A Convertible Preferred Stock [Member] | Stock Conversion 3 [Member]
Number of shareholders	16
Series A convertible preferred stock dividends (in dollars per share)	$ 243.75
Note Conversion 1 [Member]
Note conversion price (in dollars per share)	72.50
Note Conversion 2 [Member]
Note conversion price (in dollars per share)	74
Note Conversion 3 [Member]
Note conversion price (in dollars per share)	72.75
Note Conversion 4 [Member]
Note conversion price (in dollars per share)	69.25
Note Conversion 5 [Member]
Note conversion price (in dollars per share)	56.25
Note Conversion 6 [Member]
Note conversion price (in dollars per share)	50
Note Conversion 7 [Member]
Note conversion price (in dollars per share)	56.82
Note Conversion 8 [Member]
Note conversion price (in dollars per share)	50.45
Note Conversion 9 [Member]
Note conversion price (in dollars per share)	48.10
Note Conversion 10 [Member]
Note conversion price (in dollars per share)	$ 46.45

Statements of Cash Flows

Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flow from operating activities:
Net loss	$ (6,526,014)	$ (4,790,530)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	82,356	78,566
Vested stock options and warrants	165,271	871,877
Equity instruments issued for management and consulting	721,330	(6,667)
Issuance of common stock in cashless warrant exchange	736,725
Amortization of debt discount		219,097
Penalty on debt provision		10,031
(Gain) loss on Sales of Equipment	(2,387)	17,076
Gain from sale of marketable securities	(4,716)
Changes in assets and liabilities:
Accounts receivable	(636)	19,266
Inventories	(40,468)	135,627
Prepaid expense and other assets	122,943	(81,564)
Accounts payable	(430,301)	(1,544,105)
Accrued expenses	791,459	(2,415,967)
Deferred Revenue	2,998
Net cash used in operating activities:	(4,381,440)	(7,487,293)
Cash flow from investing activities:
Purchase of marketable securities	(850,000)
Proceeds from sale of marketable securities	571,887
Purchase of certificates of deposit	(1,100,000)
Redemption of certificates of deposit	1,000,000
Purchase of fixed assets	(32,760)	(32,470)
Purchase of intangibles	(11,987)	(28,095)
Net cash used in investing activities	(422,860)	(60,565)
Cash flow from financing activities:
Proceeds from long-term and convertible debt		250,000
Principal payments on debt		(933,074)
Net proceeds from issuance of preferred stock		18,950
Net proceeds from issuance of common stock	1,712,158	13,051,830
Net cash provided by financing activities	1,712,158	12,387,706
Net increase (decrease) in cash	(3,092,142)	4,839,848
Cash at beginning of period	4,856,232	16,384
Cash at end of period	1,764,090	4,856,232
Non cash transactions:
Common stock issued to satisfy debt		$ 483,478

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. August 6, 2013, December 31, 2016, 4,564,428 $.01 1 25 October 27, 2016. December 16, 2013, April 2009, 510(k) The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 Since inception to December 31, 2016, $23,950,996 $2,055,000 $13,555,003 $1,739,770 $5,685,000 Recent Accounting Developments In May 2014, 2014 09, Revenue from Contracts with Customers 606, 2015 14, “Revenue from Contracts with Customers: Deferral of the Effective Date,” 2016 08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” 2016 10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,” 2016 12, “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.” December 15, 2017, two 606. January 1, 2018, In June 2014, 2014 12, "Compensation - Stock Compensation" December 15, 2015. may In August 2014, 2014 15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern December 15, 2016, may In April 2015, 2015 03, Simplifying the Presentation of Debt Issuance Costs 2015 03 December 15, 2015. In July 2015, 2015 11 , Inventory (Topic 330): December 15, 2016, may In November 2015, 2015 17, “Income Taxes (Topic 740)” December 15, 2016 may In January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10): 2016 01”). December 15, 2017, In February 2016, 2016 02, (Topic 842” 2016 02”), December 15, 2018. In March 2016, 2016 09, “Compensation (Topic 718): (“ASU2016 09”). 2016 09 December 15, 2016. During August 2016, 2016 15, Statement of Cash Flows (Topic 230): December 15, 2017, 2016 15 We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations. Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 may may Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $71,212 2016, $8,220 2015. Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $406,000 $261,000 2016 2015, Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 605 Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY SYSTEM units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one may Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest bearing investments are those with maturities of less than one three one Investment Securities Readily marketable investments in debt and equity services are classified as available-for-sale and are reported at fair value with unrealized gains losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method. Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification 820, 820 three Level 1 Level 2 Level 3 The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1 Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements. Inventories Inventories are stated at the lower of cost or market, with cost determined on a first first December 31, December 31, 2016 2015 Finished goods $ 38,201 $ 30,237 Raw materials 165,812 162,623 Work-In-Process 68,195 38,880 Total $ 272,208 $ 231,740 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, December 31, Computers and office equipment $ 164,318 $ 153,553 Leasehold Improvements 25,635 23,874 Manufacturing Tooling 103,204 97,288 Demo Equipment 23,236 8,962 Total 316,393 283,677 Less: Accumulated Depreciation 214,897 144,079 Total Fixed Assets, Net $ 101,496 $ 139,598 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $73,249 2016 $72,275 2015. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $9,107 2016 $6,291 2015. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes (“ASC 740”) 740, The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2013 Patents and Intellectual Property On January 25th, 2014, PCT/US2014/013081 61756763 one January 25th, 2013. 148 Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 US20090216205 August 8, 2023. In July 2015, Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $1,652,438 Product Warranty Costs In 2016 2015, $34,665 $56,201 Segments The Company operates in one 2016 2015 Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

Note 2 - Development Stage Oper

Note 2 - Development Stage Operations	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Development Stage Enterprise Disclosures [Text Block]	NOTE 2 The Company was formed April 23, 2002. December 31, 2016, 4,564,428 $3,131.25.

Note 3 - Stockholders' Equity (

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 3 2015 On August 31, 2015 1,666,667 $9.00 $8.28 $0.72 8.00%) $13.8 45 250,000 1% $70,000. On August 31, 2015, 228,343 1,895,010 75,801 1,895,010 7,580,040 Each Unit consisted of one $0.01 one four February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Certificate of Designation for Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants August 31, 2020. one $123.75 Holders may Total Shares = (A x B) / C Where: · Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. · A is the total number of shares with respect to which the Series A Warrant is then being exercised. · B is the Black Scholes Value (as defined below). · C is the closing bid price of the Common Stock as of two may $0.43 The Black Scholes Value (as defined above) as of September 30, 2016 $4.319, September 30, 2016, $4.125. .40 6,141,115 September 30, 2016, 2,318,663 35,084 August 31, 2015 two $0.43 $4.319 September 30, 2016), 564 The Series A Warrants will not be exercisable or exchangeable by the holder of such warrants to the extent (and only to the extent) that the holder or any of its affiliates would beneficially own in excess of 4.99% 13(d) 1934, In addition to (but not duplicative of) the adjustments to the exercise price and the number of shares of Common Stock issuable upon exercise of the Series A Warrants in the event of stock dividends, stock splits, reorganizations or similar events, the Series A Warrants provide for certain adjustments if the Company, at any time prior to the three (1) (2) Unit Purchase Option. August 31, 2015 5% 83,333 125% $11.25 May 2016 135,995 Series B Preferred Stock. one six 4.99% Unit Exchange. February 4, 2014, $2,055,000 20,550 $0.01, $100 February 4, 2014. August 31, 2015, 228,343 3,391 3(a)(9) August 31, 2015, Redemption of Convertible Notes. $933,074 40% $1,548,792. 4. $167,031 Registered Exchange Offer for Warrants. March 25, 2016, $0.01 3,157,186 March 31, 2016, 10.05 may one tendered 10.2 one April 21, 2016. 1,770,556 tendered 18,059,671 March 31, 2016 July 6, 2016 1,251,510 20,122 2016 On November 29, 2016, $1,983,337. 756,999 $2.62 five 756,999 six $4.46 $1,739,770. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company has adopted ASC 718 Compensation-Stock Compensation 718"). 718 January 1, 2006 January 1, 2006. January 1, 2006, ASC 718 Since the Company's common stock has no significant public trading history, and the Company has experienced no significant option exercises in its history, the Company is required to take an alternative approach to estimating future volatility and estimated life and the future results could vary significantly from the Company's estimates. The Company compiled historical volatilities over a period of 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. In January 2015, $487.50 $243.75 125 16 On March 31, 2015, 6% $243.75 125 16 On June 30, 2015, 6% $243.75 125 16 For grants of stock options and warrants in 2015 1.63% 2.35% 0% 59% 66% 5 10 $6.875 $139.2375 On March 25, 2016, April 20, 2016, On July 1, 2016, 40,000 $0.01 $3.75 six first, second, third, fourth, fifth sixth On October 4, 2016, 400,000 $0.01, For grants of stock options and warrants in 2016 1.46% 2.45% 0% 59% 66% 5 10 $1.6329 $3.7195 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2014 17,945 $ 187.75 20,029 $ 198.75 Issued 14,171 69.00 303,269 123.75 Expired (766 ) 293.25 (79 ) 283.50 Exercised - - (120 ) 123.75 Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Cancelled (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 At December 31, 2016, 71,209 $21.62 9.33 114,102 2016 2015 $165,271 $871,877, $223,205 12 The following summarizes the status of options and warrants outstanding at December 31, 2016: Range of Exercise Prices Shares Weighted Average Remaining Life Options: $ 2.25 293 9.65 $ 2.42 37,152 9.64 $ 2.80 57,145 10.00 $ 3.75 44,000 9.50 $ 4.125 3,636 9.75 $ 4.1975 7,147 9.72 $ 4.25 3,529 9.25 $ 5.125 3,902 9.69 $ 65.75 342 8.81 $ 73.50 1,157 9.01 $ 77.50 2,323 8.50 $ 80.25 187 8.75 $ 86.25 232 8.25 $ 121.875 5 6.20 $ 131.25 81 5.69 $ 148.125 928 6.21 $ 150.00 1,760 5.63 $ 162.50 123 8.01 $ 206.25 121 7.75 $ 248.4375 121 6.54 $ 262.50 130 6.54 $ 281.25 529 6.04 $ 318.75 3 6.35 $ 346.875 72 7.25 $ 431.25 306 7.19 $ 468.75 133 7.15 $ 506.25 188 7.00 $ 543.75 53 6.77 $ 596.25 45 6.75 Total 165,643 Warrants: $ 4.46 756,999 4.92 $ 93.75 2,255 1.19 $ 123.75 94,085 3.67 $ 150.00 4,114 1.20 $ 225.00 107 1.07 $ 243.75 2,529 2.59 $ 281.25 5,897 0.95 $ 309.375 2,850 2.61 $ 309.50 222 2.85 $ 337.50 178 1.46 $ 371.25 944 1.41 $ 506.25 59 2.12 $ 609.375 862 2.09 Total 871,101 Stock options and warrants expire on various dates from June 2017 December 2026. At a special meeting of stockholders held on September 15, 2016, 100,000,000 200,000,000 September 16, 2016, October 26, 2016, one twenty five (1:25), 200,000,000 8,000,000 5:00 October 27, 2016, October 28, 2016. may January 29, 2017. 8,000,000 24,000,000 Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of December 31, 2016 Stock Options: Year Shares Price 2011 175 281.25 2012 1,841 131.25 – 150.00 2013 1,612 121.88 – 596.25 2014 969 162.50 – 468.75 2015 4,240 65.75 – 86.25 2016 156,806 2.25 – 5.13 Total 165,643 $ 2.25 – 596.25 Warrants: Year Shares Price 2012 2,792 281.25 2013 10,703 93.75 – 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 Total 871,101 $ 0.00 – 609.38

Note 4 - Short-term Notes Payab

Note 4 - Short-term Notes Payable	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Short-term Debt [Text Block]	NOTE 4 From July September 2014, $1.8 $1.6 “2014 $1,475,000. $122,196 2014 5,431 $100,000. April May 2015, $275,000 $250,000, 2014 “2015 2014 2015 Under a provision in the existing agreements, upon effectiveness of a resale registration statement covering certain shares, on September 9, 2014, 11%, $1,603,260 11%, 2,851 In connection with the Offering, the holders of the Convertible Notes agreed to not exercise their right to convert the Convertible Notes into shares of the Company’s common stock, in exchange for the Company’s agreement to redeem all of the outstanding Convertible Notes promptly following the consummation of the Offering at a redemption price equal to 140% August 31, 2015, $933,074 40% $1,548,792. $167,031 December 31, 2015,

Note 5 - Loss Per Share

Note 5 - Loss Per Share	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 5 The following table presents the shares used in the basic and diluted loss per common share computations: Year Ended 2016 2015 Numerator: Net loss available in basic and diluted calculation $ (6,526,014 ) $ (4,790,530 ) Other comprehensive income: Unrealized gain (loss) from marketable securities 1,501 - Comprehensive (loss) (6,524,513 ) (4,790,530 ) Denominator: Weighted average common shares outstanding-basic 2,823,345 155,233 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 2,823,345 155,233 Loss per common share-basic and diluted $ (2.31 ) $ (30.86 ) (1) December 31, 2016 December 31, 2015 1,036,744 354,449, December 31, 2016 79,246.

Note 6 - Income Taxes

Note 6 - Income Taxes	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 6– The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. There is no 100% During September 2013, 382 may September 2013, At December 31, 2015, 24.7 2016, 382 2022 13.4 December 31, 2015, 2022 2035 December 31, 2015, 9.6 $1.1 At December 31, 2016, $30.9 2017, 382 2022 $13.0 December 31, 2016, 2022 2036 December 31, 2016, $10.7 $0.2 The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change. The components of deferred income taxes at December 31, 2016 December 31, 2015 December 31, December 31, Deferred Tax Asset: Net Operating Loss $ 10,755,000 $ 10,338,000 Other 189,000 359,000 Total Deferred Tax Asset 10,944,000 10,697,000 Less Valuation Allowance 10,944,000 10,697,000 Net Deferred Income Taxes $ — $ —

Note 7 - Rent Obligation

Note 7 - Rent Obligation	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Leases of Lessee Disclosure [Text Block]	NOTE 7 The Company leases its principal office under a lease that can be cancelled after three five January 2018. $66,239 $66,345 2016 2015, The Company’s rent obligation for the next three 2017 $ 39,000 2018 $ 3,000

Note 8 - Related Party Transact

Note 8 - Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 8 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may In connection with the sale of the Series A Preferred Shares on February 4, 2014, one 19,231 $25,000 52 SOK Partners, LLC (“SOK”), a 10% July 2014 November 2014, 2014 August 2015, 140% $163,000 June 5, 2015, In connection with the Unit Exchange that was consummated on August 31, 2015, 250 2,778

Note 9 - Retirement Savings Pla

Note 9 - Retirement Savings Plans	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	NOTE 9 We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401(k) 2015, 2016, 100% 4.0% $33,143 $39,916 2016 2015. 2016 2015.

Note 10 - Supplemental Cash Flo

Note 10 - Supplemental Cash Flow Data	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	NOTE 10 Cash payments for interest were $3 $246,620 December 31, 2016 December 31, 2015,

Note 11 - Subsequent Events

Note 11 - Subsequent Events	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 11 On January 13, 2017, 1,750,000 $2.25 one 0.2 one $2.25 $3,937,500 45 175,000 35,000 $0.01 January 19, 2017. February 22, 2017, $358,312. On January 31, 2017, 8 $3,937,500 January 19, 2017. $2.5 February 15, 2017,

Note 12 - Investment Securities

Note 12 - Investment Securities and Other Comprehensive Income (Loss)	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Investment Securities and Other Comprehensive Income/(Loss) [Text Block]	NOTE 12 The cost and fair values of investment securities available-for-sale at December 31, 2016 December 31, 2016 Description Cost Gross Gross Fair Value Mutual Funds $ 282,828 $ 1,501 $ - $ 284,329

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2016
Notes to Financial Statements
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	Schedule II Valuation and Qualifying Accounts (None)

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Skyline Medical Inc. (the "Company") was incorporated under the laws of the State of Minnesota in 2002. August 6, 2013, December 31, 2016, 4,564,428 $.01 1 25 October 27, 2016. December 16, 2013, April 2009, 510(k) The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 Since inception to December 31, 2016, $23,950,996 $2,055,000 $13,555,003 $1,739,770 $5,685,000
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments In May 2014, 2014 09, Revenue from Contracts with Customers 606, 2015 14, “Revenue from Contracts with Customers: Deferral of the Effective Date,” 2016 08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” 2016 10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,” 2016 12, “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.” December 15, 2017, two 606. January 1, 2018, In June 2014, 2014 12, "Compensation - Stock Compensation" December 15, 2015. may In August 2014, 2014 15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern December 15, 2016, may In April 2015, 2015 03, Simplifying the Presentation of Debt Issuance Costs 2015 03 December 15, 2015. In July 2015, 2015 11 , Inventory (Topic 330): December 15, 2016, may In November 2015, 2015 17, “Income Taxes (Topic 740)” December 15, 2016 may In January 2016, 2016 01, Financial Instruments-Overall (Subtopic 825 10): 2016 01”). December 15, 2017, In February 2016, 2016 02, (Topic 842” 2016 02”), December 15, 2018. In March 2016, 2016 09, “Compensation (Topic 718): (“ASU2016 09”). 2016 09 December 15, 2016. During August 2016, 2016 15, Statement of Cash Flows (Topic 230): December 15, 2017, 2016 15 We reviewed all other significant newly issued accounting pronouncements and determined they are either not applicable to our business or that no material effect is expected on our financial position and results of our operations.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 may may
Use of Estimates, Policy [Policy Text Block]	Accounting Policies and Estimates The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Presentation of Taxes Collected From Customers, Policy [Policy Text Block]	Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations.
Advertising Costs, Policy [Policy Text Block]	Advertising Advertising costs are expensed as incurred. Advertising expenses were $71,212 2016, $8,220 2015.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $406,000 $261,000 2016 2015,
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Topic 13 605 Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed and determinable and collectability is probable. Delivery is considered to have occurred upon either shipment of the product or arrival at its destination based on the shipping terms of the transaction. The Company’s standard terms specify that shipment is FOB Skyline and the Company will, therefore, recognize revenue upon shipment in most cases. This revenue recognition policy applies to shipments of the STREAMWAY SYSTEM units as well as shipments of cleaning solution kits. When these conditions are satisfied, the Company recognizes gross product revenue, which is the price it charges generally to its customers for a particular product. Under the Company’s standard terms and conditions, there is no provision for installation or acceptance of the product to take place prior to the obligation of the customer. The customer’s right of return is limited only to the Company’s standard one may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three
Certificates of Deposit Policy [Policy Text Block]	Certificates of Deposit Short-term interest bearing investments are those with maturities of less than one three one
Marketable Securities, Policy [Policy Text Block]	Investment Securities Readily marketable investments in debt and equity services are classified as available-for-sale and are reported at fair value with unrealized gains losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification 820, 820 three Level 1 Level 2 Level 3 The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1
Receivables, Policy [Policy Text Block]	Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not been material to the financial statements.
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market, with cost determined on a first first December 31, December 31, 2016 2015 Finished goods $ 38,201 $ 30,237 Raw materials 165,812 162,623 Work-In-Process 68,195 38,880 Total $ 272,208 $ 231,740
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, December 31, Computers and office equipment $ 164,318 $ 153,553 Leasehold Improvements 25,635 23,874 Manufacturing Tooling 103,204 97,288 Demo Equipment 23,236 8,962 Total 316,393 283,677 Less: Accumulated Depreciation 214,897 144,079 Total Fixed Assets, Net $ 101,496 $ 139,598 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $73,249 2016 $72,275 2015.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $9,107 2016 $6,291 2015.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes (“ASC 740”) 740, The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax positions will be sustained on examination by taxing authorities, based on technical merits of the positions. The Company has identified no income tax uncertainties. Tax years subsequent to 2013
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Patents and Intellectual Property On January 25th, 2014, PCT/US2014/013081 61756763 one January 25th, 2013. 148 Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not interrupted during a surgical operation, for example, to empty a fluid collection container or otherwise dispose of the collected fluid. The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 US20090216205 August 8, 2023. In July 2015,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $1,652,438
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty Costs In 2016 2015, $34,665 $56,201
Segment Reporting, Policy [Policy Text Block]	Segments The Company operates in one 2016 2015
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, and compliance with regulations of the FDA and other governmental agencies.

Note 1 - Summary of Significa22

Note 1 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, December 31, 2016 2015 Finished goods $ 38,201 $ 30,237 Raw materials 165,812 162,623 Work-In-Process 68,195 38,880 Total $ 272,208 $ 231,740
Property Plant and Equipment UsefulLife [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3
Property, Plant and Equipment [Table Text Block]	December 31, December 31, Computers and office equipment $ 164,318 $ 153,553 Leasehold Improvements 25,635 23,874 Manufacturing Tooling 103,204 97,288 Demo Equipment 23,236 8,962 Total 316,393 283,677 Less: Accumulated Depreciation 214,897 144,079 Total Fixed Assets, Net $ 101,496 $ 139,598

Note 3 - Stockholders' Equity23

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Share-based Compensation, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2014 17,945 $ 187.75 20,029 $ 198.75 Issued 14,171 69.00 303,269 123.75 Expired (766 ) 293.25 (79 ) 283.50 Exercised - - (120 ) 123.75 Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Cancelled (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Exercise Prices Shares Weighted Average Remaining Life Options: $ 2.25 293 9.65 $ 2.42 37,152 9.64 $ 2.80 57,145 10.00 $ 3.75 44,000 9.50 $ 4.125 3,636 9.75 $ 4.1975 7,147 9.72 $ 4.25 3,529 9.25 $ 5.125 3,902 9.69 $ 65.75 342 8.81 $ 73.50 1,157 9.01 $ 77.50 2,323 8.50 $ 80.25 187 8.75 $ 86.25 232 8.25 $ 121.875 5 6.20 $ 131.25 81 5.69 $ 148.125 928 6.21 $ 150.00 1,760 5.63 $ 162.50 123 8.01 $ 206.25 121 7.75 $ 248.4375 121 6.54 $ 262.50 130 6.54 $ 281.25 529 6.04 $ 318.75 3 6.35 $ 346.875 72 7.25 $ 431.25 306 7.19 $ 468.75 133 7.15 $ 506.25 188 7.00 $ 543.75 53 6.77 $ 596.25 45 6.75 Total 165,643 Warrants: $ 4.46 756,999 4.92 $ 93.75 2,255 1.19 $ 123.75 94,085 3.67 $ 150.00 4,114 1.20 $ 225.00 107 1.07 $ 243.75 2,529 2.59 $ 281.25 5,897 0.95 $ 309.375 2,850 2.61 $ 309.50 222 2.85 $ 337.50 178 1.46 $ 371.25 944 1.41 $ 506.25 59 2.12 $ 609.375 862 2.09 Total 871,101
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Stock Options: Year Shares Price 2011 175 281.25 2012 1,841 131.25 – 150.00 2013 1,612 121.88 – 596.25 2014 969 162.50 – 468.75 2015 4,240 65.75 – 86.25 2016 156,806 2.25 – 5.13 Total 165,643 $ 2.25 – 596.25 Warrants: Year Shares Price 2012 2,792 281.25 2013 10,703 93.75 – 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 Total 871,101 $ 0.00 – 609.38

Note 5 - Loss Per Share (Tables

Note 5 - Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended 2016 2015 Numerator: Net loss available in basic and diluted calculation $ (6,526,014 ) $ (4,790,530 ) Other comprehensive income: Unrealized gain (loss) from marketable securities 1,501 - Comprehensive (loss) (6,524,513 ) (4,790,530 ) Denominator: Weighted average common shares outstanding-basic 2,823,345 155,233 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 2,823,345 155,233 Loss per common share-basic and diluted $ (2.31 ) $ (30.86 )

Note 6 - Income Taxes (Tables)

Note 6 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, December 31, Deferred Tax Asset: Net Operating Loss $ 10,755,000 $ 10,338,000 Other 189,000 359,000 Total Deferred Tax Asset 10,944,000 10,697,000 Less Valuation Allowance 10,944,000 10,697,000 Net Deferred Income Taxes $ — $ —

Note 7 - Rent Obligation (Table

Note 7 - Rent Obligation (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Rent Expense [Table Text Block]	2017 $ 39,000 2018 $ 3,000

Note 12 - Investment Securiti27

Note 12 - Investment Securities and Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2016
Notes Tables
Schedule of Available-for-sale Securities Reconciliation [Table Text Block]	December 31, 2016 Description Cost Gross Gross Fair Value Mutual Funds $ 282,828 $ 1,501 $ - $ 284,329

Note 1 - Summary of Significa28

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Nov. 29, 2016USD ($)	Oct. 27, 2016	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Oct. 04, 2016$ / shares
Common Stock, Shares, Outstanding | shares			4,564,428	208,258	4,564,428
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.01	$ 0.01	$ 0.01	$ 0.01
Stockholders' Equity, Period Increase (Decrease)			$ 23,950,996
Stock Issued During Period, Value, New Issues				$ 13,060,880
Debt Instrument, Increase (Decrease), Net					$ 5,685,000
Advertising Expense			71,212	8,220
Research and Development Expense			406,000	261,000
Depreciation			73,249	72,275
Amortization of Intangible Assets			9,107	6,291
Cash, Uninsured Amount			1,652,438		1,652,438
Product Warranty Expense			$ 34,665	56,201
Number of Operating Segments			1
Non-US [Member]
Revenues			$ 0	$ 0
Earliest Tax Year [Member]
Open Tax Year			2,013
IPO [Member]
Stock Issued During Period, Value, New Issues					13,555,003
The 2016 Registered Direct Offering [Member]
Stock Issued During Period, Value, New Issues			$ 1,625,905
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs	$ 1,739,770				1,739,770
Series A Convertible Preferred Stock [Member] | Private Placement [Member]
Stock Issued During Period, Value, New Issues					$ 2,055,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		25

Note 1 - Summary of Significa29

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Finished goods	$ 38,201	$ 30,237
Raw materials	165,812	162,623
Work-In-Process	68,195	38,880
Total	$ 272,208	$ 231,740

Note 1 - Summary of Significa30

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	12 Months Ended
	Dec. 31, 2016
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	5 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significa31

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Property, Plant, and Equipment Gross	$ 316,393	$ 283,677
Less: Accumulated Depreciation	214,897	144,079
Total Fixed Assets, Net	101,496	139,598
Office Equipment [Member]
Property, Plant, and Equipment Gross	164,318	153,553
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	25,635	23,874
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	103,204	97,288
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 23,236	$ 8,962

Note 2 - Development Stage Op32

Note 2 - Development Stage Operations (Details Textual) - $ / shares	Dec. 31, 2016	Sep. 30, 2016
Common Stock, Shares, Issued	4,564,428
Share Price		$ 4.125
Common Stock [Member]
Share Price	$ 3,131.25

Note 3 - Stockholders' Equity33

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual)	Nov. 29, 2016USD ($)$ / sharesshares	Oct. 27, 2016	Oct. 04, 2016$ / sharesshares	Jul. 01, 2016$ / sharesshares	Mar. 31, 2016shares	Aug. 31, 2015USD ($)$ / sharesshares	Jun. 30, 2015$ / sharesshares	Mar. 31, 2015$ / sharesshares	Feb. 04, 2014USD ($)$ / sharesshares	May 31, 2016shares	Jan. 31, 2015$ / sharesshares	Jul. 06, 2016shares	Sep. 30, 2016$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Oct. 26, 2016shares	Sep. 15, 2016shares	Sep. 14, 2016shares	Apr. 21, 2016shares	Mar. 25, 2016$ / sharesshares
Shares Issued, Price Per Share | $ / shares						$ 9
Underwriter Price | $ / shares						8.28
Underwriting Discount | $ / shares						$ 0.72
Underwriting Commission						8.00%
Proceeds from Issuance or Sale of Equity | $						$ 13,800,000
Option Granted to Underwriter to Purchase Additional Units Period						45 days
Option Granted to Underwriter to Purchase Additional Units Number of Units Granted						250,000
Underwriting Agreement Non-accountable Expense Allowance Percentage						1.00%
Common Stock, Par or Stated Value Per Share | $ / shares			$ 0.01											$ 0.01	$ 0.01	$ 0.01
Share Price | $ / shares													$ 4.125
Class of Warrant or Right, Outstanding														871,101		871,101
Stock Issued During Period, Value, New Issues | $															$ 13,060,880
Stock Issued During Period, Shares, New Issues			400,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate														0.00%	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum														59.00%	59.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum														66.00%	66.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number														71,209		71,209
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares														$ 21.62		$ 21.62
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term														9 years 120 days
Class of Warrant or Right Number of Warrants Vested and Exercisable														114,102	114,102	114,102
Allocated Share-based Compensation Expense | $														$ 165,271	$ 871,877
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $														$ 223,205		$ 223,205
Common Stock, Shares Authorized														24,000,000	24,000,000	24,000,000	8,000,000	200,000,000	100,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		25
Purchasers [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities							125	125			125
Preferred Stock Conversion Price Per Share | $ / shares											$ 487.50
Conversion of Stock Price Per Share | $ / shares							$ 243.75	$ 243.75			$ 243.75
Number of Preferred Stock Share holders							16	16			16
Preferred Stock, Dividend Rate, Percentage							6.00%	6.00%
Vice President of Sales [Member]
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.01
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares				$ 3.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				40,000
Number of Equal Installments Options are Expected to Vest				6
The 2016 Registered Direct Offering [Member]
Proceeds from Issuance or Sale of Equity | $	$ 1,983,337
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 4.46
Share Price | $ / shares	$ 2.62
Stock Issued During Period, Value, New Issues | $														$ 1,625,905
Stock Issued During Period, Shares, New Issues	756,999
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	756,999
Class of Warrant or Right Term	5 years
Class of Warrant or Right, Vesting Period	180 days
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $	$ 1,739,770															$ 1,739,770
The Convertible Notes [Member]
Debt Instrument Redemption Principal Amount | $						$ 933,074
Debt Instrument Redemption Premium Percentage						40.00%
Debt Instrument Redemption Price | $						$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates | $						$ 167,031
Series B Convertible Preferred Stock [Member]
Beneficial Ownership Limitation Percentage						4.99%
Stock Issued During Period, Value, New Issues | $									$ 2,055,000
Stock Issued During Period, Shares, New Issues									20,550
Preferred Stock Par Value | $ / shares									$ 0.01
Preferred Stock Stated Value | $ / shares									$ 100
Series A Warrants [Member] | Exchange Offer [Member]
Stock to be Issued for Exchange Offer, Shares, Maximum																					3,157,186
Cashless Exercise of Common Stock Warrants, Total					10.05
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																				1,770,556
Exchange from Series B Warrants to Warrant Shares [Member] | Exchange Offer [Member]
Common Stock, Par or Stated Value Per Share | $ / shares																					$ 0.01
Series B Warrants [Member] | Exchange Offer [Member]
Class of Warrant or Right Exercised During Period												1,251,510
Stock Issued During Period Shares Warrants Exercised												20,122
Cashless Exercise of Common Stock Warrants, Total					10.2
Class of Warrant or Right, Number of Securities Called by Warrants or Rights																				18,059,671
Common Stock [Member]
Share Price | $ / shares														$ 3,131.25		$ 3,131.25
Stock Issued During Period Shares Warrants Exercised														2,318,663	120
Stock Issued During Period, Value, New Issues | $															$ 667
Stock Issued During Period, Shares, New Issues															66,667
Common Stock [Member] | The 2016 Registered Direct Offering [Member]
Stock Issued During Period, Value, New Issues | $														$ 7,570
Stock Issued During Period, Shares, New Issues														756,999
Common Stock [Member] | Series B Warrants [Member]
Stock Issued During Period Shares Warrants Exercised														628,237
Corporate Stock Transfer Inc. [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit						1
Common Stock, Par or Stated Value Per Share | $ / shares						$ 0.01
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right						1							0.4
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares						$ 123.75
Cash Less Exercise Formula Definition of Letter C in the Formula Closing Bid Price Number of Trading Days Prior to the Time of Exercise						2 days
Cash Less Exercise Formula Closing Bid Price Per Share Minimum to Be Used in the Formula | $ / shares						$ 0.43
Warrants Option to Settle in Cash Fair Value Disclosure | $ / shares													$ 4.319
Class of Warrant or Right Exercised During Period													6,141,115
Stock Issued During Period Shares Warrants Exercised													2,318,663
Class of Warrant or Right, Outstanding						35,084
Class of Warrant or Right Cash less Exercise Common Stock Price That Would Result in a Dilutive Exercise | $ / shares						$ 0.43
Beneficial Ownership Limitation Percentage						4.99%
Class of Warrant or Right Period Over Which Additional Adjustments to Price and Number of Shares May Be Made						3 years
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member] | Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member]
Stock Issued During Period Shares Warrants Exercised													564
Corporate Stock Transfer Inc. [Member] | Series B Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit						1
Corporate Stock Transfer Inc. [Member] | Series A Convertible Preferred Stock [Member]
Unit Agreement Number of Shares of Common Stock Included in Each Unit						4
Maximum [Member]
Underwriting Agreement Expenses Agreed to Reimburse the Underwriter | $						$ 70,000
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 609.38		609.38
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period														3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period														10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate														2.45%	2.35%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term															10 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares														$ 596.25	$ 139.2375
Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term														10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares														$ 3.7195
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares														$ 0		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period														3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate														1.46%	1.63%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term														5 years	5 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares														$ 2.25	$ 6.875
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares														$ 1.6329
Exchange Units [Member]
Unit Purchase Option Units Sold						1,666,667
Stock Issued During Period, Shares, Conversion of Convertible Securities						1,895,010
Exchange Units [Member] | Series A Warrants [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities						7,580,040
Exchange Units [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities						75,801
Exchange Units [Member] | Series B Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities						1,895,010
Exchange Units [Member] | Corporate Stock Transfer Inc. [Member]
Unit Purchase Option Units Issued						228,343
Stock Issued During Period, Shares, Conversion of Convertible Securities										135,995
Unit Purchase Option Number of Units Available for Underwriter to Purchase, Percentage						5.00%
Unit Purchase Option Number of Units Available For Underwriter to Purchase						83,333
Unit Purchase Option Exercise Price, Percentage						125.00%
Unit Purchase Option Exercise Price | $ / shares						$ 11.25
Exchange Units [Member] | Series A Convertible Preferred Stock [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities						3,391

Note 3 - Stockholders' Deficit,

Note 3 - Stockholders' Deficit, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Options exercise price (in dollars per share)	$ 65.75
Number of Shares Outstanding (in shares)	165,643
Warrant [Member]
Number of Shares Outstanding (in shares)	323,099	20,029
Average Exercise Price Outstanding (in dollars per share)	$ 128.40	$ 198.75
Number of Shares Issued (in shares)	1,487,881	303,269
Average Exercise Price Issued (in dollars per share)	$ 0.71	$ 123.75
Number of Shares Expired (in shares)		(79)
Average Exercise Price Expired (in dollars per share)		$ 283.50
Number of Shares Exercised (in shares)	(939,879)	(120)
Average Exercise Price Exercised (in dollars per share)		$ 123.75
Number of Shares Outstanding (in shares)	871,101	323,099
Average Exercise Price Outstanding (in dollars per share)	$ 52.22	$ 128.40
Number of Shares Cancelled (in shares)
Employee Stock Option [Member]
Number of Shares Outstanding (in shares)	31,350	17,945
Average Exercise Price Outstanding (in dollars per share)	$ 133.23	$ 187.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	157,982	14,171
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 3.14	$ 69
Number of Shares Expired (in shares)		(766)
Average Exercise Price Expired (in dollars per share)		$ 293.25
Number of Shares Exercised (in shares)	(1,312)
Options exercise price (in dollars per share)	$ 65.75
Number of Shares Outstanding (in shares)	165,643	31,350
Average Exercise Price Outstanding (in dollars per share)	$ 11.22	$ 133.23
Number of Shares Cancelled (in shares)	(22,377)
Average Exercise Price Cancelled (in dollars per share)	$ 122.13

Note 3 - Stockholders' Defici35

Note 3 - Stockholders' Deficit, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Shares, options (in shares)	165,643
Weighted average remaining life, options (Year)
Shares, warrants (in shares)	871,101
Weighted average remaining life, warrants (Year)
Warrant One [Member]
Price, warrants (in dollars per share) | $ / shares	$ 4.46
Shares, warrants (in shares)	756,999
Weighted average remaining life, warrants (Year)	4 years 335 days
Warrant Two [Member]
Price, warrants (in dollars per share) | $ / shares	$ 93.75
Shares, warrants (in shares)	2,255
Weighted average remaining life, warrants (Year)	1 year 69 days
Warrant Three [Member]
Price, warrants (in dollars per share) | $ / shares	$ 123.75
Shares, warrants (in shares)	94,085
Weighted average remaining life, warrants (Year)	3 years 244 days
Warrant Four [Member]
Price, warrants (in dollars per share) | $ / shares	$ 150
Shares, warrants (in shares)	4,114
Weighted average remaining life, warrants (Year)	1 year 73 days
Warrant Five [Member]
Price, warrants (in dollars per share) | $ / shares	$ 225
Shares, warrants (in shares)	107
Weighted average remaining life, warrants (Year)	1 year 25 days
Warrant Six [Member]
Price, warrants (in dollars per share) | $ / shares	$ 243.75
Shares, warrants (in shares)	2,529
Weighted average remaining life, warrants (Year)	2 years 215 days
Warrant Seven [Member]
Price, warrants (in dollars per share) | $ / shares	$ 281.25
Shares, warrants (in shares)	5,897
Weighted average remaining life, warrants (Year)	346 days
Warrant Eight [Member]
Price, warrants (in dollars per share) | $ / shares	$ 309.375
Shares, warrants (in shares)	2,850
Weighted average remaining life, warrants (Year)	2 years 222 days
Warrant Nine [Member]
Price, warrants (in dollars per share) | $ / shares	$ 309.50
Shares, warrants (in shares)	222
Weighted average remaining life, warrants (Year)	2 years 310 days
Warrant Ten [Member]
Price, warrants (in dollars per share) | $ / shares	$ 337.50
Shares, warrants (in shares)	178
Weighted average remaining life, warrants (Year)	1 year 167 days
Warrant Eleven [Member]
Price, warrants (in dollars per share) | $ / shares	$ 371.25
Shares, warrants (in shares)	944
Weighted average remaining life, warrants (Year)	1 year 149 days
Warrant Twelve [Member]
Price, warrants (in dollars per share) | $ / shares	$ 506.25
Shares, warrants (in shares)	59
Weighted average remaining life, warrants (Year)	2 years 43 days
Warrant Thirteen [Member]
Price, warrants (in dollars per share) | $ / shares	$ 609.375
Shares, warrants (in shares)	862
Weighted average remaining life, warrants (Year)	2 years 32 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.25
Shares, options (in shares)	293
Weighted average remaining life, options (Year)	9 years 237 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.42
Shares, options (in shares)	37,152
Weighted average remaining life, options (Year)	9 years 233 days
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.80
Shares, options (in shares)	57,145
Weighted average remaining life, options (Year)	10 years
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 3.75
Shares, options (in shares)	44,000
Weighted average remaining life, options (Year)	9 years 182 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.125
Shares, options (in shares)	3,636
Weighted average remaining life, options (Year)	9 years 273 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.1975
Shares, options (in shares)	7,147
Weighted average remaining life, options (Year)	9 years 262 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.25
Shares, options (in shares)	3,529
Weighted average remaining life, options (Year)	9 years 91 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 5.125
Shares, options (in shares)	3,902
Weighted average remaining life, options (Year)	9 years 251 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 65.75
Shares, options (in shares)	342
Weighted average remaining life, options (Year)	8 years 295 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 73.50
Shares, options (in shares)	1,157
Weighted average remaining life, options (Year)	9 years 3 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 77.50
Shares, options (in shares)	2,323
Weighted average remaining life, options (Year)	8 years 182 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 80.25
Shares, options (in shares)	187
Weighted average remaining life, options (Year)	8 years 273 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 86.25
Shares, options (in shares)	232
Weighted average remaining life, options (Year)	8 years 91 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 121.875
Shares, options (in shares)	5
Weighted average remaining life, options (Year)	6 years 73 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 131.25
Shares, options (in shares)	81
Weighted average remaining life, options (Year)	5 years 251 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 148.125
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	6 years 76 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 150
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	5 years 229 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 162.50
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	8 years 3 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 206.25
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	7 years 273 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 248.4375
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	6 years 197 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 262.50
Shares, options (in shares)	130
Weighted average remaining life, options (Year)	6 years 197 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 281.25
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	6 years 14 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 318.75
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	6 years 127 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	7 years 91 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	7 years 69 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 468.75
Shares, options (in shares)	133
Weighted average remaining life, options (Year)	7 years 54 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	7 years
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 543.75
Shares, options (in shares)	53
Weighted average remaining life, options (Year)	6 years 281 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 596.25
Shares, options (in shares)	45
Weighted average remaining life, options (Year)	6 years 273 days

Note 3 - Stockholders' Equity36

Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Shares, options (in shares)	165,643
Shares, warrants (in shares)	871,101
Minimum [Member]
Price, options (in dollars per share)	$ 2.25	$ 6.875
Price, warrants (in dollars per share)	0
Maximum [Member]
Price, options (in dollars per share)	596.25	$ 139.2375
Price, warrants (in dollars per share)	$ 609.38
Warrants 2012 [Member]
Shares, warrants (in shares)	2,792
Price, warrants (in dollars per share)	$ 281.25
Warrants 2013 [Member]
Shares, warrants (in shares)	10,703
Warrants 2013 [Member] | Minimum [Member]
Price, warrants (in dollars per share)	$ 93.75
Warrants 2013 [Member] | Maximum [Member]
Price, warrants (in dollars per share)	$ 371.25
Warrants 2014 [Member]
Shares, warrants (in shares)	6,455
Warrants 2014 [Member] | Minimum [Member]
Price, warrants (in dollars per share)	$ 243.75
Warrants 2014 [Member] | Maximum [Member]
Price, warrants (in dollars per share)	$ 609.38
Warrants 2015 [Member]
Shares, warrants (in shares)	94,152
Warrants 2015 [Member] | Minimum [Member]
Price, warrants (in dollars per share)	$ 0
Warrants 2015 [Member] | Maximum [Member]
Price, warrants (in dollars per share)	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares)	756,999
Price, warrants (in dollars per share)	$ 4.46
Stock Options 2011 [Member]
Shares, options (in shares)	175
Price, options (in dollars per share)	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares)	1,841
Stock Options 2012 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 131.25
Stock Options 2012 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 150
Stock Options 2013 [Member]
Shares, options (in shares)	1,612
Stock Options 2013 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 121.88
Stock Options 2013 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares)	969
Stock Options 2014 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 162.50
Stock Options 2014 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 468.75
Stock Options 2015 [Member]
Shares, options (in shares)	4,240
Stock Options 2015 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 65.75
Stock Options 2015 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares)	156,806
Stock Options 2016 [Member] | Minimum [Member]
Price, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] | Maximum [Member]
Price, options (in dollars per share)	$ 5.13

Note 4 - Short-term Notes Pay37

Note 4 - Short-term Notes Payable (Details Textual) - USD ($)	Aug. 31, 2015	May 31, 2015	Sep. 30, 2014	Dec. 31, 2015	Sep. 09, 2014
The 2014 Convertible Notes [Member]
Debt Instrument, Face Amount			$ 1,800,000
Debt Instrument Reduced Face Amount			1,600,000		$ 1,603,260
Proceeds from Convertible Debt			1,475,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					2,851
Percentage Reduction to Debt Instrument Face Amount					11.00%
Percentage Reduction to Number of Warrants					11.00%
The 2014 Convertible Notes [Member] | SOK Partners LLC [Member]
Debt Instrument, Face Amount			122,196
Proceeds from Convertible Debt			$ 100,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			5,431
The 2015 Convertible Notes [Member]
Debt Instrument, Face Amount		$ 275,000
Proceeds from Convertible Debt		$ 250,000
Class of Warrant or Right Issued During Period		0
The Convertible Notes [Member]
Debt Instrument, Redemption Price, Percentage				140.00%
Debt Instrument Redemption Principal Amount	$ 933,074
Debt Instrument Redemption Premium Percentage	40.00%
Debt Instrument Redemption Price	$ 1,548,792
Debt Instrument Redemption Amount Paid to Affiliates	$ 167,031
Short-term Debt				$ 0

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,036,744	354,449
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 5 - Loss Per Share - Share

Note 5 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Net loss available in basic and diluted calculation		$ (6,526,014)	$ (4,790,530)
Unrealized gain (loss) from marketable securities		1,501
Comprehensive (loss)		$ (6,524,513)	$ (4,790,530)
Weighted average common shares outstanding-basic (in shares)		2,823,345	155,233
Effect of dilutive stock options, warrants and preferred stock (1) (in shares)	[1]
Loss per common share - basic and diluted (in dollars per share)		$ (2.31)	$ (30.86)
[1]	The number of shares underlying options and warrants outstanding as of December 31, 2016 and December 31, 2015 are 1,036,744 and 354,449, respectively. The number of shares underlying the preferred stock as of December 31, 2016 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 6 - Income Taxes (Details

Note 6 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Valuation Allowance Percentage	100.00%
Income Tax Expense (Benefit)	$ 0
Domestic Tax Authority [Member]
Operating Loss Carryforwards	30,900	$ 24,700
Operating Loss Carryforwards, Valuation Allowance	10,700	9,600
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	13,000	13,400
Operating Loss Carryforwards, Valuation Allowance	$ 200	$ 1,100

Note 6 - Income Taxes - Compone

Note 6 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Net Operating Loss	$ 10,755,000	$ 10,338,000
Other	189,000	359,000
Total Deferred Tax Asset	10,944,000	10,697,000
Less Valuation Allowance	10,944,000	10,697,000
Net Deferred Income Taxes	$ 0	$ 0

Note 7 - Rent Obligation (Detai

Note 7 - Rent Obligation (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Lessee Leasing Arrangements Operating Leases Terms of Contract Cancellation	3 years
Lessee Leasing Arrangements Operating Leases Extension Term	5 years
Operating Leases, Rent Expense	$ 66,239	$ 66,345

Note 7 - Rent Obligation - Rent

Note 7 - Rent Obligation - Rent Obligation (Details)	Dec. 31, 2016USD ($)
2,017	$ 39,000
2,018	$ 3,000

Note 8 - Related Party Transa44

Note 8 - Related Party Transactions (Details Textual) - USD ($)	Oct. 04, 2016	Aug. 31, 2015	Feb. 04, 2014	Aug. 31, 2015	Dec. 31, 2015	Jul. 31, 2014
Stock Issued During Period, Shares, New Issues	400,000
Stock Issued During Period, Value, New Issues					$ 13,060,880
Common Stock [Member]
Stock Issued During Period, Shares, New Issues					66,667
Stock Issued During Period, Value, New Issues					$ 667
Chief Executive Officer [Member] | Stock Conversion from Series A Convertible Stock to Exchange Units [Member]
Conversion of Stock, Shares Converted		250
Conversion of Stock, Shares Issued		2,778
Chief Executive Officer [Member] | Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			52
Chief Executive Officer [Member] | Series A Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues			19,231
Stock Issued During Period, Value, New Issues			$ 25,000
SOK Partners LLC [Member]
Ownership Percentage						10.00%
SOK Partners LLC [Member] | The Convertible Notes [Member]
Debt Instrument, Redemption Price, Percentage				140.00%
Repayments of Related Party Debt				$ 163,000

Note 9 - Retirement Savings P45

Note 9 - Retirement Savings Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Defined Contribution Plan, Employer Matching Contribution, Percent of Match	100.00%	100.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	4.00%	4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 33,143	$ 39,916

Note 10 - Supplemental Cash F46

Note 10 - Supplemental Cash Flow Data (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Interest Paid	$ 3	$ 246,620

Note 11 - Subsequent Events (De

Note 11 - Subsequent Events (Details Textual) - USD ($)	Feb. 22, 2017	Jan. 19, 2017	Oct. 04, 2016	Aug. 31, 2015	Sep. 30, 2016
Stock Issued During Period, Shares, New Issues			400,000
Share Price					$ 4.125
Proceeds from Issuance or Sale of Equity				$ 13,800,000
Subsequent Event [Member] | The 2017 Public Offering [Member]
Stock Issued During Period, Shares, New Issues		1,750,000
Share Price		$ 2.25
Proceeds from Issuance or Sale of Equity		$ 3,937,500
Subsequent Event [Member] | The 2017 Public Offering [Member] | Series D Warrants [Member]
Class of Warrant or Right, Issued per Unit		0.2
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right		1
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 2.25
Subsequent Event [Member] | Over-Allotment Option [Member]
Proceeds from Issuance or Sale of Equity	$ 358,312
Sale of Stock, Underwriter Option Term		45 days
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase		175,000
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase		35,000
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase		$ 0.01

Note 12 - Investment Securiti48

Note 12 - Investment Securities and Other Comprehensive Income (Loss) - Cost and Fair Values of Investment Securities Available-for-sale (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Fair Value	$ 284,329
Mutual Fund [Member]
Cost	282,828
Gross Unrealized Gains	1,501
Gross Unrealized Losses
Fair Value	$ 284,329